AI English summary of an SEC filing — figures as filed

The company said Simon Herriott, currently President, Health & Biosciences, will leave IFF on March 31, 2025, as announced on February 20, 2025.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Feb 20, 2025Period of report Feb 20, 2025Summary published (UTC) Oct 16, 2026

Key points

AI summary

The company said Simon Herriott, currently President, Health & Biosciences, will leave IFF on March 31, 2025, as announced on February 20, 2025.
The company said Mr. Herriott's departure will be treated as a qualifying event under IFF's executive severance policy.
IFF said Leticia Goncalves Lourenço will join as President of the Health & Biosciences division effective March 1, 2025.
In Item 5.02, the company disclosed that successor Leticia Goncalves Lourenço will join on March 1, 2025, and Simon Herriott will depart on March 31, 2025.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Simon Herriott to Leave IFF

The company said Simon Herriott, currently President, Health & Biosciences, will leave IFF on March 31, 2025, as announced on February 20, 2025.

Source · Based on the filing body and exhibits

Herriott Departure Treated Under Executive Severance Policy

The company said Mr. Herriott's departure will be treated as a qualifying event under IFF's executive severance policy.

Source · Based on the filing body and exhibits

Leticia Goncalves Lourenço Named President

IFF said Leticia Goncalves Lourenço will join as President of the Health & Biosciences division effective March 1, 2025.

Source · Based on the filing body and exhibits

Successor Start Date and Departure Timing

In Item 5.02, the company disclosed that successor Leticia Goncalves Lourenço will join on March 1, 2025, and Simon Herriott will depart on March 31, 2025.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.